Skip to Main Content

Author Details

Andrew Loblaw
Princess Margaret Hospital, University of Toronto
1995
267
55
PMIDPaper TitleJournal TitlePublished Year
37979707Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).Int J Radiat Oncol Biol Phys2024
37863241Safety of Ultrahypofractionated Pelvic Nodal Irradiation in the Definitive Management of Prostate Cancer: Systematic Review and Meta-analysis.Int J Radiat Oncol Biol Phys2024
37661040Stereotactic Body Radiation Therapy: A Radiosurgery Society Guide to the Treatment of Localized Prostate Cancer Illustrated by Challenging Cases.Pract Radiat Oncol2024
37838556Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).Eur Urol Oncol2024
36218318An environmental scan of sexual health services for cancer survivors among Canadian institutions.Can Urol Assoc J2023
37619656Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.Radiother Oncol2023
37776903Response to comment to "Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer".Radiother Oncol2023
37921936The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?World J Urol2023
37126232Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.J Urol2023
37419394To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36754232Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.Radiother Oncol2023
36750891Clinical implementation of magnetic resonance imaging simulation for radiation oncology planning: 5 year experience.Radiat Oncol2023
34836735Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis.Clin Oncol (R Coll Radiol)2022
35644708Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy.Clin Oncol (R Coll Radiol)2022
35500786A comparative study of patient-reported outcomes after contemporary radiation techniques for prostate cancer.Radiother Oncol2022
35494042Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol.Front Oncol2022
35427550In Reply to Yamazaki et al.Int J Radiat Oncol Biol Phys2022
35420695Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial.JAMA Oncol2022
35817321Can a FLAME forge a stronger SABRe? Let's await the evidence for focal boost with Stereotactic Ablative Radiotherapy.Radiother Oncol2022
35718075A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients.Pract Radiat Oncol2022
35875062Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer.Front Oncol2022
36289518Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update.Syst Rev2022
36113498Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.Lancet Oncol2022
35151715Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?Radiother Oncol2022
35302473Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer.Can Urol Assoc J2022
34993496Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG Adv2022
35133265Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline.Can Urol Assoc J2022
34637882Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost.Int J Radiat Oncol Biol Phys2022
34812728Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer.Can Urol Assoc J2022
34812724Target prostate biopsies: How best to report in synoptic format?Can Urol Assoc J2022
32966843Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis.Radiother Oncol2021
33493615Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.Int J Radiat Oncol Biol Phys2021
33538782Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol2021
33497248Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.J Clin Oncol2021
34940084Delivery of Virtual Care in Oncology: Province-Wide Interprofessional Consensus Statements Using a Modified Delphi Process.Curr Oncol2021
34585025Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.Adv Radiat Oncol2021
34400038Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer: an Updated Systematic Review.Clin Oncol (R Coll Radiol)2021
34487764Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials.Radiother Oncol2021
34420861Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy.Brachytherapy2021
34324914Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.Radiother Oncol2021
34237473Moving Unfavorable Small-Bowel Anatomy Away From the Prostate to Optimize Radiation Therapy Plans With the GU-Lok.Pract Radiat Oncol2021
34089752Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.Radiother Oncol2021
33172830Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study.Radiother Oncol2021
33359269Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial.Radiother Oncol2021
32918971Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.Radiother Oncol2021
32938571Hospital-level Effects Contribute to Variations in Prostate Cancer Quality of Care.Eur Urol Oncol2021
31161221Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.J Natl Cancer Inst2020
33521396Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of <sup>18</sup>F-DCFPyL PET/CT Restaging.Adv Radiat Oncol2020
31787501Ultrahypofractionation Should be a Standard of Care Option for Intermediate-Risk Prostate Cancer.Clin Oncol (R Coll Radiol)2020
31730876A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.Int J Radiat Oncol Biol Phys2020
  • 1 - 50 of 267

Recommended Authors

Robert T Dess
University of Michigan ann arbor
Career Start Year 2016
Number of shared co-authors 32
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 38
Kiri A Sandler
Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 16
Stephen Greco
Johns Hopkins University School of Medicine
Career Start Year 2012
Number of shared co-authors 25
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 29
Bradley J Stish
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 26
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 21
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 11
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 13
Albert J Chang
University of California Los Angeles
Career Start Year 2003
Number of shared co-authors 35
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 1
Brian J Moran
Chicago Prostate Cancer Center
Career Start Year 1999
Number of shared co-authors 19
Daniel J Krauss
William Beaumont School of Medicine
Career Start Year 1999
Number of shared co-authors 23
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 33
Danny Y Song
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 26
Wolfgang Lilleby
Oslo University Hospital
Career Start Year 1999
Number of shared co-authors 21
Brian J Davis
Mayo Clinic
Career Start Year 1997
Number of shared co-authors 34
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 24
Eric M Horwitz
Fox Chase Cancer Center
Career Start Year 1996
Number of shared co-authors 43
Jay P Ciezki
Cleveland Clinic
Career Start Year 1995
Number of shared co-authors 23
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 21
Almudena Zapatero
University Hospital La Princesa
Career Start Year 1995
Number of shared co-authors 33
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 24
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 21
Theodore L DeWeese
Johns Hopkins University School of Medicine
Career Start Year 1991
Number of shared co-authors 28
Jeff M Michalski
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 31
Anthony V D'Amico
Duke University Medical Center
Career Start Year 1988
Number of shared co-authors 36
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 35
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 28

Collaborators

Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Co-authored papers 42
Stanley K Liu
Odette Cancer Centre, University of Toronto
Co-authored papers 24
Edward Chow
University of Toronto
Co-authored papers 18
Masoom A Haider
University Health Network
Co-authored papers 15
Richard Choo
Mayo Clinic
Co-authored papers 15
Antonio Finelli
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Co-authored papers 14
Joseph L Chin
University of Western Ontario
Co-authored papers 12
John Trachtenberg
University of Toronto, University Health Network
Co-authored papers 11
Kristina Commisso
University Health Network
Co-authored papers 11
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Co-authored papers 11
Glenn Bauman
Western University and London Regional Cancer Program
Co-authored papers 8
Neil E Fleshner
University of Toronto
Co-authored papers 8
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Co-authored papers 7
Ants Toi
Mount Sinai Hospital, University of Toronto
Co-authored papers 6
Mark K Buyyounouski
Stanford University
Co-authored papers 5
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 5
Eric Vigneault
Centre Hospitalier Universitaire de Quebec
Co-authored papers 5
Amar U Kishan
University of California los angeles
Co-authored papers 5
Fred Saad
University of Montreal Health Center
Co-authored papers 5
Andrew Warner
Western University and London Regional Cancer Program
Co-authored papers 4
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 4
Alan W Katz
University of Rochester
Co-authored papers 4
Katherine A Siminovitch
University of Toronto, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital
Co-authored papers 4
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Co-authored papers 4
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 4
Michael L Steinberg
University of California los angeles
Co-authored papers 4
Jure Murgic
University Hospital Center Sestre Milosrdnice
Co-authored papers 4
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Co-authored papers 4
Constantine A Mantz
University of Chicago
Co-authored papers 4
Release 1.2